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Introduction
Ponatinib is a third-generation tyrosine kinase 
inhibitor (TKI) used in treatment of refractory 
chronic myeloid leukemia (CML) and Philadelphia 
chromosome positive acute lymphoblastic leukemia 
(Ph+ ALL). Cutaneous adverse events associated with 
its use include nonspecific skin eruptions and dry 
skin [1]. We report the case of a patient treated with 
ponatinib who developed a prominent ichthyosiform 
drug eruption.
Case Synopsis
A 76-year-old man with refractory Ph+ ALL presented 
with a mildly pruritic, scaly, thickened rash. His 
leukemia was previously treated with CD19 chimeric 
antigen receptor (CAR) T-cell therapy, followed by 
ponatinib 15mg daily combined with mercaptopurine, 
vincristine, methotrexate, and prednisone (POMP) 
maintenance; subsequently, ponatinib 30mg daily 
was administered as a single agent. The patient 
reported he previously had a similar rash with prior 
ponatinib exposure, which resolved with “shedding” 
of the thickened skin without other sequelae upon 
ponatinib holiday.
Skin examination revealed thickened ichthyosiform 
plate-like shiny patches with scale distributed diffusely 
on the forehead, trunk, and extremities bilaterally. The 
patient also had poorly demarcated erythematous 
patches with areas of sparing on the abdomen (Figure 
1). A biopsy of the rash from the forearm revealed 
histologic features resembling lamellar ichthyosis: 
compact predominantly ortho-hyperkeratosis with 
focal parakeratosis, normal granular cell layer and 
sparse perivascular lymphocytic infiltrate (Figure 2). 
The patient did not tolerate topical urea or topical 
retinoids owing to secondary xerosis and cracking. 
Topical corticosteroids caused associated burning 
and he declined systemic retinoids. He had moderate 
improvement with petrolatum/lanolin ointment and 
was able to continue this TKI.
Case Discussion
Cutaneous eruptions are common side effects of 
TKIs used in the treatment of leukemia. The most 
commonly described dermatologic adverse events 
for TKIs include maculopapular rash, pruritus, and 
xerosis [2]. These toxicities can be challenging to 
manage owing to their symptoms, visibility, and 
frequency and can result in dose reduction or 
discontinuation of anti-cancer therapy.
Abstract
Cutaneous adverse events are commonly experienced 
with use of tyrosine kinase inhibitors in the treatment 
of leukemia and typically include nonspecific 
cutaneous eruptions and xerosis. We report the case 
of a man who experienced an ichthyosiform drug 
eruption while taking ponatinib, a third-generation 
tyrosine kinase inhibitor. Disruption of epidermal 
growth pathways through inhibition of various 
receptor tyrosine kinases by ponatinib may offer 
insights into the pathophysiologic mechanisms 
behind acquired ichthyosis.
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As a rationally designed TKI with specificity for both 
wild-type and mutated Bcr-Abl as well as other 
targets, ponatinib has demonstrated efficacy in the 
treatment of imatinib-resistant leukemias and other 
malignancies such as gastrointestinal stromal tumors 
(GIST). Low grade skin eruptions and dry skin were 
the most common non-hematologic adverse events 
experienced by patients in a phase II clinical trial of 
ponatinib, occurring in 34% and 32% of patients, 
respectively [1]. In a phase 3 trial of ponatinib versus 
imatinib for the treatment of newly diagnosed CML, 
the ponatinib treatment group experienced a higher 
incidence of rash (37% versus 16%), dry skin (18% 
versus 3%), and pruritus (18% versus 8%) compared 
to the imatinib treatment group [3]. This trial was 
terminated early after twelve months owing to non-
cutaneous serious adverse events in the ponatinib 
treatment group.
To date, there have been two reported cases of 
ponatinib causing an ichthyosiform drug eruption 
[4, 5]. Other reports have documented ponatinib-
induced keratosis pilaris-like, lichen plano-pilaris-
like, and pityriasis rubra pilaris-like eruptions as 
well as folliculocentric and seborrheic changes [2, 
4]. The mechanism behind this reaction is poorly 
understood, but we postulate that the inhibition 
of various receptor tyrosine kinases by ponatinib, 
including VEGFR, FGFR, and the Src family of kinases 
[6] may result in the disruption of epidermal growth 
pathways. Specifically, Fyn, a member of the Src 
family of kinases has been shown to play an active 
role in keratinocyte differentiation control [7] and 
may be a target of study for new insights into the 
pathophysiology of acquired ichthyosis.
Conclusion
In conclusion, we present the case of a patient who 
developed an ichthyosiform drug eruption while 
being treated with the TKI ponatinib. Improvement of 
this eruption upon drug interruption and recurrence 
with drug re-introduction supports the assumption 
that this eruption is ponatinib-induced. Further 
classification of the cutaneous toxicities associated 
with ponatinib may provide insight into various 
pathophysiologic mechanisms and kinase targets 
affecting normal skin function. Early recognition and 
	
	
	
	
	
	
	
	
	
Figure 1. Clinical findings of ichthyosiform eruption associated 
with ponatinib. Ichthyosiform plate-like shiny scaly patches 
distributed diffusely on the trunk and extremities.
	
	
	
	
	
	
	
	
	
	
Figure 2. Biopsy of the left forearm demonstrating compact 
hyperkeratosis associated with an intact granular cell layer and 
very sparse inflammatory cell infiltrate in the superficial dermis, 
H&E, 100%.
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treatment of these cutaneous adverse events allows 
for conservative management and improvement of 
patient quality of life without discontinuation of anti-
cancer therapy.
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